CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 4.4

ph-index = 13

Forward Citations = 503(Granted Patents)

Location History:

Hertfordshire, GB (1993)
Watford Harts, GB (1997)
Watford, GB (1993 - 2003)
St. Neots, GB (2013)
Puckeridge, GB (2001 - 2015)

Company Filing History:

24 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Calliditas Therapeutics Suisse Sa

patents

6. 1 out of 53

Chdi Foundation, Inc.

patents

7. 1 out of 19

Neumora Therapeutics, Inc.

patents

Years Active: 1993-2025

Loading Chart...

43 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12281116 - HTT modulators for treating Huntington's disease (2025-04-21),

2. 12202816 - Compounds as NADPH oxidase inhibitors (2025-01-21),

3. 12152038 - Vasopressin receptor antagonists and products and methods related thereto (2024-11-26),

4. 9212173 - Pyrazole aminopyrimidine derivatives as LRRK2 modulators (2015-12-15),

5. 9145402 - Aminopyrimidine derivatives as LRRK2 modulators (2015-09-29),

6. 8815882 - Pyrazole aminopyrimidine derivatives as LRRK2 modulators (2014-08-26),

7. 8809331 - Aminopyrimidine derivatives as LRRK2 modulators (2014-08-19),

8. 8802674 - Aminopyrimidine derivatives as LRRK2 modulators (2014-08-12),

9. 8796296 - Aminopyrimidine derivatives as LRRK2 modulators (2014-08-05),

10. 8791130 - Aminopyrimidine derivatives as LRRK2 modulators (2014-07-29),

11. 8354420 - Aminopyrimidine derivatives as LRRK2 inhibitors (2013-01-15),

12. 7592456 - [object Object] (2009-09-22),

13. 7482457 - Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands (2009-01-27),

14. 7271191 - Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease (2007-09-18),

15. 7176203 - Imidazo-triazine derivatives as ligands for gaba receptors (2007-02-13),

Hello! I'm glad to assist you with the article about inventor Mark Stewart Chambers.

Title: Innovator Spotlight: Mark Stewart Chambers - Pioneering Solutions for Parkinson's Disease

Introduction:

Mark Stewart Chambers, a talented inventor hailing from Puckeridge, GB, has made significant contributions in the field of pharmaceuticals and biotechnology. With an impressive portfolio of 40 patents, his innovative spirit shines through in his latest groundbreaking patents related to Parkinson's disease.

Latest Patents:

Chambers' recent patents include "Pyrazole aminopyrimidine derivatives as LRRK2 modulators" and "Aminopyrimidine derivatives as LRRK2 modulators." These patents focus on compounds that modulate the LRRK2 receptor, offering promising treatment approaches for diseases such as Parkinson's.

Career Highlights:

Having worked with renowned companies like Merck Sharp & Dohme Corporation (known as Merck) and Genentech, Inc., Chambers has honed his skills and expertise in pharmaceutical research and development. His innovative solutions have the potential to revolutionize the treatment of neurological disorders.

Collaborations:

Throughout his career, Chambers has collaborated with esteemed professionals in the industry, including Philip Jones and Charles Baker-Glenn. These collaborations have fostered a culture of innovation and knowledge sharing, leading to groundbreaking advancements in pharmaceutical science.

Conclusion:

Mark Stewart Chambers' dedication to developing novel treatments for Parkinson's disease exemplifies his passion for making a positive impact on global healthcare. With a keen focus on innovation and collaboration, Chambers continues to inspire the scientific community with his pioneering inventions.

This text is generated by artificial intelligence and may not be accurate.